NO316027B1 - Fremgangsmåter for screening av substanser med en modulerende virkning på en interleukin-5-reseptoravhengig cellul¶r signaloverföringsvei,samt pattedyrceller - Google Patents
Fremgangsmåter for screening av substanser med en modulerende virkning på en interleukin-5-reseptoravhengig cellul¶r signaloverföringsvei,samt pattedyrceller Download PDFInfo
- Publication number
- NO316027B1 NO316027B1 NO19954781A NO954781A NO316027B1 NO 316027 B1 NO316027 B1 NO 316027B1 NO 19954781 A NO19954781 A NO 19954781A NO 954781 A NO954781 A NO 954781A NO 316027 B1 NO316027 B1 NO 316027B1
- Authority
- NO
- Norway
- Prior art keywords
- receptor
- cells
- interleukin
- subunit
- recombinant dna
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000001419 dependent effect Effects 0.000 title claims abstract description 39
- 102000010786 Interleukin-5 Receptors Human genes 0.000 title claims description 106
- 108010038484 Interleukin-5 Receptors Proteins 0.000 title claims description 106
- 210000004962 mammalian cell Anatomy 0.000 title claims description 23
- 230000008054 signal transmission Effects 0.000 title abstract description 11
- 238000012216 screening Methods 0.000 title abstract description 9
- 230000037361 pathway Effects 0.000 title description 9
- 230000001413 cellular effect Effects 0.000 title description 3
- 230000000897 modulatory effect Effects 0.000 title description 2
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 54
- 230000001105 regulatory effect Effects 0.000 claims abstract description 42
- 238000012360 testing method Methods 0.000 claims abstract description 36
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 19
- 230000008859 change Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 194
- 108020003175 receptors Proteins 0.000 claims description 117
- 102000005962 receptors Human genes 0.000 claims description 115
- 230000019491 signal transduction Effects 0.000 claims description 58
- 108010002616 Interleukin-5 Proteins 0.000 claims description 48
- 229940100602 interleukin-5 Drugs 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 27
- 239000013612 plasmid Substances 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 108060001084 Luciferase Proteins 0.000 claims description 11
- 210000005260 human cell Anatomy 0.000 claims description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 108700025906 fos Genes Proteins 0.000 claims description 7
- 230000001960 triggered effect Effects 0.000 claims description 7
- 108010038452 Interleukin-3 Receptors Proteins 0.000 claims description 6
- 230000003042 antagnostic effect Effects 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 claims description 4
- 102000010790 Interleukin-3 Receptors Human genes 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 102100039897 Interleukin-5 Human genes 0.000 claims 6
- 241001529936 Murinae Species 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012106 screening analysis Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 55
- 102000000743 Interleukin-5 Human genes 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102100039064 Interleukin-3 Human genes 0.000 description 22
- 108010002386 Interleukin-3 Proteins 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- 229940076264 interleukin-3 Drugs 0.000 description 21
- 230000000638 stimulation Effects 0.000 description 21
- 230000006698 induction Effects 0.000 description 19
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 239000012636 effector Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 7
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 7
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 5
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 5
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 102000003675 cytokine receptors Human genes 0.000 description 5
- 108010057085 cytokine receptors Proteins 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 150000001982 diacylglycerols Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 102000055228 human IL5 Human genes 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 1
- 101100452011 Homo sapiens ICAM1 gene Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000145847 Moria Species 0.000 description 1
- 101000960966 Mus musculus Interleukin-5 Proteins 0.000 description 1
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108010002724 Pheromone Receptors Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000254058 Photinus Species 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000002427 pheromone receptor Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical group C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4317577A DE4317577A1 (de) | 1993-05-27 | 1993-05-27 | Verfahren zum Screenen von Substanzen mit modulierender Wirkung auf einen Interleukin-5-Rezeptor-abhängigen zellulären Signalübertragungsweg |
| PCT/EP1994/001735 WO1994028170A1 (de) | 1993-05-27 | 1994-05-27 | Verfahren zum screenen von substanzen mit modulierender wirkung auf einen interleukin-5-rezeptor-abhängigen zellulären signalübertragungsweg |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO954781D0 NO954781D0 (no) | 1995-11-24 |
| NO954781L NO954781L (no) | 1996-01-23 |
| NO316027B1 true NO316027B1 (no) | 2003-12-01 |
Family
ID=6488996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19954781A NO316027B1 (no) | 1993-05-27 | 1995-11-24 | Fremgangsmåter for screening av substanser med en modulerende virkning på en interleukin-5-reseptoravhengig cellul¶r signaloverföringsvei,samt pattedyrceller |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5922549A (sv) |
| EP (1) | EP0701628B1 (sv) |
| JP (1) | JPH08510643A (sv) |
| KR (1) | KR100318188B1 (sv) |
| CN (1) | CN1125467A (sv) |
| AT (1) | ATE162555T1 (sv) |
| AU (1) | AU691816B2 (sv) |
| CA (1) | CA2163549A1 (sv) |
| DE (2) | DE4317577A1 (sv) |
| DK (1) | DK0701628T3 (sv) |
| ES (1) | ES2113109T3 (sv) |
| FI (1) | FI111016B (sv) |
| HU (1) | HU220345B (sv) |
| NO (1) | NO316027B1 (sv) |
| NZ (1) | NZ291131A (sv) |
| RU (1) | RU2139936C1 (sv) |
| WO (1) | WO1994028170A1 (sv) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405350D0 (en) * | 1994-03-18 | 1994-05-04 | Sandoz Ltd | Organic compounds |
| US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
| US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
| US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
| US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
| US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| AU2001296607A1 (en) * | 2000-10-03 | 2002-04-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | High efficiency regulatable gene expression system |
| WO2004042007A2 (en) * | 2002-10-30 | 2004-05-21 | University Of Iowa Research Foundation | Somatic cell gene targeting vectors and methods of use thereof |
| US20040209246A1 (en) * | 2003-04-15 | 2004-10-21 | Agouron Pharmaceuticals, Inc. | Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors |
| US20050112551A1 (en) * | 2003-11-24 | 2005-05-26 | Agouron Pharmaceuticals, Inc. | Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US5401629A (en) * | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| US5453491A (en) * | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
| WO1992013063A1 (en) * | 1991-01-18 | 1992-08-06 | Oncogene Science, Inc. | Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes |
| CA2120518C (en) * | 1991-10-01 | 1998-10-13 | Monika Konig | A method of identifying ligands and antagonists of ligands |
-
1993
- 1993-05-27 DE DE4317577A patent/DE4317577A1/de not_active Withdrawn
-
1994
- 1994-05-27 NZ NZ291131A patent/NZ291131A/en unknown
- 1994-05-27 AT AT94918807T patent/ATE162555T1/de not_active IP Right Cessation
- 1994-05-27 JP JP7500238A patent/JPH08510643A/ja not_active Ceased
- 1994-05-27 DK DK94918807T patent/DK0701628T3/da active
- 1994-05-27 DE DE59405120T patent/DE59405120D1/de not_active Expired - Fee Related
- 1994-05-27 EP EP94918807A patent/EP0701628B1/de not_active Expired - Lifetime
- 1994-05-27 KR KR1019950705282A patent/KR100318188B1/ko not_active IP Right Cessation
- 1994-05-27 ES ES94918807T patent/ES2113109T3/es not_active Expired - Lifetime
- 1994-05-27 CA CA002163549A patent/CA2163549A1/en not_active Abandoned
- 1994-05-27 WO PCT/EP1994/001735 patent/WO1994028170A1/de active IP Right Grant
- 1994-05-27 RU RU95122776/13A patent/RU2139936C1/ru not_active IP Right Cessation
- 1994-05-27 CN CN94192453A patent/CN1125467A/zh active Pending
- 1994-05-27 AU AU69977/94A patent/AU691816B2/en not_active Ceased
- 1994-05-27 HU HU9503363A patent/HU220345B/hu not_active IP Right Cessation
- 1994-05-27 US US08/553,304 patent/US5922549A/en not_active Expired - Lifetime
-
1995
- 1995-11-24 NO NO19954781A patent/NO316027B1/no not_active IP Right Cessation
- 1995-11-27 FI FI955700A patent/FI111016B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2139936C1 (ru) | 1999-10-20 |
| US5922549A (en) | 1999-07-13 |
| DK0701628T3 (da) | 1998-09-21 |
| EP0701628A1 (de) | 1996-03-20 |
| NO954781L (no) | 1996-01-23 |
| DE59405120D1 (de) | 1998-02-26 |
| DE4317577A1 (de) | 1994-12-01 |
| ATE162555T1 (de) | 1998-02-15 |
| KR960702532A (ko) | 1996-04-27 |
| FI955700A (sv) | 1995-11-27 |
| CA2163549A1 (en) | 1994-12-08 |
| KR100318188B1 (ko) | 2002-06-20 |
| AU6997794A (en) | 1994-12-20 |
| FI111016B (sv) | 2003-05-15 |
| HU9503363D0 (en) | 1996-01-29 |
| CN1125467A (zh) | 1996-06-26 |
| WO1994028170A1 (de) | 1994-12-08 |
| HUT73742A (en) | 1996-09-30 |
| AU691816B2 (en) | 1998-05-28 |
| EP0701628B1 (de) | 1998-01-21 |
| NZ291131A (en) | 1996-10-28 |
| FI955700A0 (sv) | 1995-11-27 |
| JPH08510643A (ja) | 1996-11-12 |
| ES2113109T3 (es) | 1998-04-16 |
| HU220345B (hu) | 2001-12-28 |
| NO954781D0 (no) | 1995-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB | |
| Gutman et al. | The collagenase gene promoter contains a TPA and oncogene‐responsive unit encompassing the PEA3 and AP‐1 binding sites. | |
| Chaturvedi et al. | Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs | |
| Inoue et al. | Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells | |
| Bunone et al. | Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. | |
| Guerrini et al. | Cis-and trans-acting elements involved in amino acid regulation of asparagine synthetase gene expression | |
| Ponglikitmongkol et al. | Synergistic activation of transcription by the human estrogen receptor bound to tandem responsive elements. | |
| Bittorf et al. | Activation of the transcription factor NF-κB by the erythropoietin receptor: structural requirements and biological significance | |
| JPH07505046A (ja) | レセプター依存細胞シグナル誘導経路に関する調節効果を有する物質のスクリーニング法 | |
| Lin et al. | Identification and regulation of human PDE5A gene promoter | |
| Kadri et al. | Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation | |
| Pierrat et al. | Functional analysis of the human estrogen receptor using a phenotypic transactivation assay in yeast | |
| NO316027B1 (no) | Fremgangsmåter for screening av substanser med en modulerende virkning på en interleukin-5-reseptoravhengig cellul¶r signaloverföringsvei,samt pattedyrceller | |
| Marden et al. | Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia | |
| Choi et al. | Molecular cloning and sequence analysis of the rat liver carnitine octanoyltransferase cDNA, its natural gene and the gene promoter | |
| Yamada et al. | Characterization of alternatively spliced isoforms of the type I interleukin-1 receptor on iNOS induction in rat hepatocytes | |
| Mariner et al. | IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor α promoter | |
| Kumar et al. | Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb | |
| van Hille et al. | Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents | |
| HODNY et al. | Sp1 and chromatin environment are important contributors to the formation of repressive chromatin structures on the transfected human adenine nucleotide translocase-2 promoter | |
| JPH06153958A (ja) | 発現ベクターおよび治療学的応用のためのｈｉｖ耐性ヒト細胞の調製におけるそれらの使用 | |
| GUIZANI et al. | Mechanisms in interleukin-2 protection against glucocorticoid-induced apoptosis: regulation of AP-1 and glucocorticoid receptor transcriptional activities | |
| DELRIEU et al. | Inhibition of interleukin-6 promoter activity by the 24 kDa isoform of fibroblast growth factor-2 in HeLa cells | |
| Prassolov et al. | Functional identification of secondary mutations inducing autonomous growth in synergy with a truncated interleukin-3 receptor: implications for multi-step oncogenesis | |
| JP2000253889A (ja) | 転写促進能の測定用細胞 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |